ARMGO Pharma, Inc., is a privately held biopharmaceutical company dedicated to applying original, targeted science to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular, and neurological disorders.
  The company’s proprietary drugs, known as “Rycals” are a new class of oral agents that act on a novel therapeutic target, the ryanodine receptor/calcium release channel (RyR) located on the sarcoplasmic/endoplasmic reticulum of the cell. Rycal compounds act to stabilize these channels and repair the calcium leak caused by stress associated with chronic diseases. It is hypothesized that the leak in the RyR channels, if left untreated, may contribute to disorders affecting the heart, skeletal muscle, and the brain.

Rycal compounds have the potential to act selectively on these RyR channels, functioning as calcium release channel stabilizers.

  ARMGO Pharma, Inc., has been awarded an exclusive, worldwide license from Columbia University for its ryanodine receptor technology.

Current News


ARMGO Pharma Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for ARM210/S48168 for the Treatment of Duchenne Muscular Dystrophy   Link to Article


ARMGO Pharma and Servier Announce Advancement of Rycal ARM210/S48168 into Clinical Stage Program Targeting Duchenne Muscular Dystrophy   Link to Article


ARMGO Pharma Receives Research Grant Award from Kennedy's Disease Association to Support Advancement of Rycal Compounds   Link to Article


ARMGO Pharma Receives $1 Million Award from MDA to Support Advancement of Rycal Compound ARM210 as a Novel Treatment for Duchenne Muscular Dystrophy   Link to Article


ARMGO Pharma, Inc. announces the appointment of Dr. Sapan Shah as CEO   Link to Article


Kushnir A, Marks AR. The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol. 2010;59:1-30.   Link to Article


Kushnir A, Shan J, Betzenhauser MJ, Reiken S, Marks AR. Role of CaMKlldelta phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. Proc Natl Acad Sci U S A. 2010 Jun1;107(22):10274-9.   Link to Article


Kushnir A, Betzenhauser MJ, Marks AR. Ryanodine receptor studies using genetically engineered mice.FEBS Lett. 2010 May 17;584(10):1956-65.   Link to Article


Betzenhauser MJ, Marks AR. Ryanodine Receptor channelopathies Pflugers Arch. 2010 Jul;460(2):467-80.   Link to Article


Fauconnier J, Thireau J, Reiken S, Cassan C, Richard S, Matecki S, Marks AR,Lacampagne A.- Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy.Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1559-64.4-9.   Link to Article

Prof. Andrew Marks presentation on, "Mechanism-Based Therapies for Heart Failure and Cardiac Arrhythmias" from the Henry Stewart Talks, Series, "Calcium Signalling: Regulation, Mechanisms, Effectors, Role in Disease and Recent Advances".
Link to Presentation